Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Advances in Hybrid and Molecular Tumor Imaging
share announcement

Advances in Hybrid and Molecular Tumor Imaging

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".

Deadline for manuscript submissions: closed (31 July 2022) | Viewed by 5831

Special Issue Editors

Dr. Irene Burger

E-Mail Website
Guest Editor
Department of Nuclear Medicine, Universitats Spital Zurich, Zurich, Switzerland
Interests: hybrid and molecular tumor imaging; time-of-flight PET/MRI
Prof. Sergio Baldari

E-Mail Website
Guest Editor
Dipartimento di Scienze biomediche, odontoiatriche e delle immagini morfologiche e funzionali, Università degli Studi di Messina, Messina, Italy
Interests: hybrid and molecular tumor imaging; time-of-flight PET/MRI

Special Issue Information

Dear Colleagues,

Background: Over the last four decades, [18F]FDG positron emission tomography (PET) gained wide clinical acceptance in molecular imaging providing additional information to conventional imaging about pathophysiology. Newer advanced and innovative PET technology is now available, such as improved detectors and software technology (i.e., digital detectors, higher time resolution and whole body detectors as well as TOF, point spread function and penalized-likelihood reconstruction algorithms). All these resulted in significant advancement of PET image quality and reduced radiotracer dose and scanning time.

But not only technology has improved in the recent past. With the increase of new tracers available for PET imaging the frontiers for disease detection, therapy selection and response assessment based on PET are steadily increasing, as has been shown impressively by the successful implementation of PSMA-PET.

Goal: The aim of this Special Issue is to summarize the most promising technical applications and improvements, with both reviews and original works. The focus on improved accuracy of molecular imaging over conventional imaging shall add justification of novel technologies to improve clinical management by insights into pathophysiology. To further enhance the acceptance of molecular imaging, new promising applications of available radiopharmaceuticals as well as new targets and tracers shall be presented. Finally the use of artificial intelligence applications and PET/MRI to combine molecular information from different techniques are topic to be considered.

Before the community embarks on a disruptive imaging approach of molecular imaging, it is fundamental to investigate the obvious PET and conventional imaging synergies and challenges for the dissemination and application of these novelties, considering the promising perspectives in several scenarios.

Scope and information for Authors: In this Special Issue, we will collect reviews or original data with a focus on novel insights in molecular imaging, covering both new radiopharmaceuticals and technological improvements.

Dr. Irene Burger
Prof. Sergio Baldari
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nuclear medicine
  • radiology
  • medical imaging
  • machine learning
  • artificial intelligence in diagnostics

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 1364 KiB  
Article
[68Ga]DOTATOC PET/CT Radiomics to Predict the Response in GEP-NETs Undergoing [177Lu]DOTATOC PRRT: The “Theragnomics” Concept
by Riccardo Laudicella, Albert Comelli, Virginia Liberini, Antonio Vento, Alessandro Stefano, Alessandro Spataro, Ludovica Crocè, Sara Baldari, Michelangelo Bambaci, Desiree Deandreis, Demetrio Arico’, Massimo Ippolito, Michele Gaeta, Pierpaolo Alongi, Fabio Minutoli, Irene A. Burger and Sergio Baldari
Cancers 2022, 14(4), 984; https://doi.org/10.3390/cancers14040984 - 16 Feb 2022
Cited by 22 | Viewed by 3200
Abstract
Despite impressive results, almost 30% of NET do not respond to PRRT and no well-established criteria are suitable to predict response. Therefore, we assessed the predictive value of radiomics [68Ga]DOTATOC PET/CT images pre-PRRT in metastatic GEP NET. We retrospectively analyzed the [...] Read more.
Despite impressive results, almost 30% of NET do not respond to PRRT and no well-established criteria are suitable to predict response. Therefore, we assessed the predictive value of radiomics [68Ga]DOTATOC PET/CT images pre-PRRT in metastatic GEP NET. We retrospectively analyzed the predictive value of radiomics in 324 SSTR-2-positive lesions from 38 metastatic GEP-NET patients (nine G1, 27 G2, and two G3) who underwent restaging [68Ga]DOTATOC PET/CT before complete PRRT with [177Lu]DOTATOC. Clinical, laboratory, and radiological follow-up data were collected for at least six months after the last cycle. Through LifeX, we extracted 65 PET features for each lesion. Grading, PRRT number of cycles, and cumulative activity, pre- and post-PRRT CgA values were also considered as additional clinical features. [68Ga]DOTATOC PET/CT follow-up with the same scanner for each patient determined the disease status (progression vs. response in terms of stability/reduction/disappearance) for each lesion. All features (PET and clinical) were also correlated with follow-up data in a per-site analysis (liver, lymph nodes, and bone), and for features significantly associated with response, the Δradiomics for each lesion was assessed on follow-up [68Ga]DOTATOC PET/CT performed until nine months post-PRRT. A statistical system based on the point-biserial correlation and logistic regression analysis was used for the reduction and selection of the features. Discriminant analysis was used, instead, to obtain the predictive model using the k-fold strategy to split data into training and validation sets. From the reduction and selection process, HISTO_Skewness and HISTO_Kurtosis were able to predict response with an area under the receiver operating characteristics curve (AUC ROC), sensitivity, and specificity of 0.745, 80.6%, 67.2% and 0.722, 61.2%, 75.9%, respectively. Moreover, a combination of three features (HISTO_Skewness; HISTO_Kurtosis, and Grading) did not improve the AUC significantly with 0.744. SUVmax, however, could not predict the response to PRRT (p = 0.49, AUC 0.523). The presented preliminary “theragnomics” model proved to be superior to conventional quantitative parameters to predict the response of GEP-NET lesions in patients treated with complete [177Lu]DOTATOC PRRT, regardless of the lesion site. Full article
(This article belongs to the Special Issue Advances in Hybrid and Molecular Tumor Imaging)
►▼ Show Figures

Figure 1

19 pages, 7579 KiB  
Article
68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in Recurrent Prostate Cancer: Diagnostic Performance and Association with Clinical and Histopathological Data
by Paola Mapelli, Samuele Ghezzo, Ana Maria Samanes Gajate, Erik Preza, Anna Palmisano, Vito Cucchiara, Giorgio Brembilla, Carolina Bezzi, Riccardo Rigamonti, Patrizia Magnani, Elisa Toninelli, Valentino Bettinardi, Nazareno Suardi, Luigi Gianolli, Paola Scifo, Alberto Briganti, Francesco De Cobelli, Antonio Esposito and Maria Picchio
Cancers 2022, 14(2), 334; https://doi.org/10.3390/cancers14020334 - 11 Jan 2022
Cited by 11 | Viewed by 2028
Abstract
The aim of the present study is to investigate and compare the performances of 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in identifying recurrent prostate cancer (PCa) after primary treatment and to explore the association of dual-tracer PET findings with clinical and histopathological characteristics. [...] Read more.
The aim of the present study is to investigate and compare the performances of 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in identifying recurrent prostate cancer (PCa) after primary treatment and to explore the association of dual-tracer PET findings with clinical and histopathological characteristics. Thirty-five patients with biochemical relapse (BCR) of PCa underwent 68Ga PSMA PET/MRI for restaging purpose, with 31/35 also undergoing 68Ga-DOTA-RM2 PET/MRI scan within 16 days (mean: 3 days, range: 2–16 days). Qualitative and quantitative image analysis has been performed by comparing 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI findings both on a patient and lesion basis. Clinical and instrumental follow-up was used to validate PET findings. Fisher’s exact test and Mann-Whitney U test were used to investigate the association between dual-tracer PET findings, clinical and histopathological data. p-value significance was defined below the 0.05 level. Patients’ mean age was 70 years (range: 49–84) and mean PSA at time of PET/MR scans was 1.88 ng/mL (range: 0.21–14.4). A higher detection rate was observed for 68Ga-PSMA PET/MRI, with more lesions being detected compared to 68Ga-DOTA-RM2 PET/MRI (26/35 patients, 95 lesions vs. 15/31 patients, 41 lesions; p = 0.016 and 0.002). 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI findings were discordant in 11/31 patients; among these, 10 were 68Ga-PSMA positive (9/10 confirmed as true positive and 1/10 as false positive by follow-up examination). Patients with higher levels of PSA and shorter PSA doubling time (DT) presented more lesions on 68Ga-PSMA PET/MRI (p = 0.006 and 0.044), while no association was found between PET findings and Gleason score. 68Ga-PSMA has a higher detection rate than 68Ga-DOTA-RM2 in detecting PCa recurrence. The number of 68Ga-PSMA PET positive lesions is associated with higher levels of PSA and shorter PSA DT, thus representing potential prognostic factors. Full article
(This article belongs to the Special Issue Advances in Hybrid and Molecular Tumor Imaging)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop